-
Posted by
Two Blokes Jun 4 -
Filed in
Stock
-
7 views
NanoViricides (NYSE-A:NNVC) said it is advancing its measles drug development program with a new animal trial to evaluate its antiviral candidate NV-387. The company has commissioned a study using specially modified mice that express the human SLAM/CD150 protein, a key receptor the measles virus uses to infect cells.
